Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL552171 | 0.85 | TDP1 (0.42) | ARHTR2AIDH1HTR2CHTR2B | |
| SCHEMBL3751942 | 0.83 | KDM4E (0.43) | ARHTR2AIDH1HTR2CHTR2B | |
| SCHEMBL3748708 | 0.77 | AR (0.42) | ARRORCFFAR1FFAR4NR3C1 | |
| SCHEMBL27263524 | 0.76 | PPARG (0.41) | HTR2AALDH1A1KDM4EUSP2MAOB | |
| SCHEMBL22519888 | 0.76 | IDO1 (0.55) | ALDH1A1KDM4EMAOB | |
| SCHEMBL18213822 | 0.75 | RORC (0.43) | ARHTR2AIDH1HTR2CHTR2B | |
| SCHEMBL20817916 | 0.75 | MPO (0.38) | ARHTR2AIDH1HTR2CHTR2B | |
| SCHEMBL17631638 | 0.75 | AR (0.52) | ARIDH1SQORFFAR1FFAR4 | |
| SCHEMBL12200028 | 0.74 | IDO1 (0.53) | ALDH1A1KDM4EMAOB | |
| SCHEMBL15132099 | 0.74 | IDO1 (0.53) | ALDH1A1KDM4EMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550764-B2 | Fused heterocyclic compounds and their use | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-01-24 | — | — | US | disclosed |
| US-9550764-B2 | Fused heterocyclic compounds and their use | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-01-24 | — | — | US | disclosed |
| US-9550764-B2 | Fused heterocyclic compounds and their use | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-01-24 | — | — | US | disclosed |
| EP-2888254-B1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | CANCER RES INST ROYAL (GB) | 2016-10-05 | — | — | EP | disclosed |
| EP-2888254-B1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | CANCER RES INST ROYAL (GB) | 2016-10-05 | — | — | EP | disclosed |
| US-20150232462-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232462-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232462-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-2888254-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014030001-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014030001-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232462-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KRAS | AR 257/4885HTR2A 2948/4885IDH1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.